(CercleFinance.com) – Nicox jumped 11% after its announcement that annual worldwide net sales of the NCX 470 could potentially reach at least $300 million within eight years of commercial launches in the United States and China.
The ophthalmology company cites a market study in the United States carried out by an independent agency, a study aimed at evaluating the commercial potential of its flagship product in development for the reduction of intraocular pressure (IOP).
“The market research also provided insights to inform our selling price and reimbursement strategy, which were taken into account for our assessment of potential revenue,” said Andreas Segerros, CEO of Nicox. .